drugset / Trial / NCT02615730
PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib/IIa, open-label, non-randomized, dose-escalation, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and clinical activity of oral GSK2636771 in combination with intravenous (IV) paclitaxel in two independent subject populations: subjects with PTEN-deficient, advanced gastric adenocarcinoma.
Timeline
- Start
- 2016-02
- Primary completion
- 2021-03-31
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2636771 | Small molecule | 300 mg | Oral |
| Subject | GSK2636771 | Small molecule | 400 mg | Oral |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |